#China #Shanghai #Mitral Regurgitation #KingstronBio #ProStyle M®

Significant Breakthrough in Heart Valve Technology

On March 12, 2026, KingstronBio Technology (Changshu) Co., Ltd. celebrated a significant milestone when it successfully performed the first implantation of its innovative ProStyle M® Transcatheter Mitral Valve System. This pioneering procedure took place under pure ultrasound guidance as part of a national multicenter confirmatory study, laying the foundation for advanced research in the realm of structural heart disease treatments.

The Vision Behind ProStyle M®

The ProStyle M® system is designed to address the growing health concern of mitral regurgitation (MR), which is recognized as the most common valvular heart issue in China. With a focus on improving patient outcomes, KingstronBio has developed this technology to not only enhance the quality of life for individuals suffering from MR but also to reduce the complexities involved in valve replacements. The procedure was overseen by noted cardiothoracic specialists Professor Wang Chunsheng and Professor Wei Lai from the Department of Cardiac Surgery at Zhongshan Hospital, affiliated with Fudan University.

Previous Findings and Study Framework

Prior to the multicenter study, KingstronBio conducted a two-year First-in-Man (FIM) trial involving 10 patients with an average age of 71. This initial study revealed promising results, with no instances of regurgitation, suggesting effective anchoring and sealing capabilities of the implant. These findings have bolstered the confidence of medical professionals in the potential clinical efficacy of the ProStyle M® system.

Overcoming Technical Challenges

The development of the ProStyle M® system came in response to numerous technical challenges historically associated with transcatheter mitral valve replacements (TMVR). Key hurdles include navigating complex anatomical structures and ensuring robust anchoring to prevent left ventricular outflow tract obstruction. The design of the ProStyle M® system aims to simplify surgical procedures while enhancing hemodynamic performance, which is crucial for the long-term success of such interventions.

Innovative Patented Technologies

KingstronBio has prioritized innovation as a core pillar of its mission. The ProStyle M® system incorporates proprietary technologies such as the Micro-Ex™ anti-calcification treatment, which is designed to enhance the durability of cardiac valves by reducing calcification—a common complication in heart valve prosthetics. Additionally, the AirBo™ dry storage technology significantly augments the valve's resilience and compatibility with human tissue, ensuring better performance over time.

A Comprehensive Approach to Heart Valve Issues

KingstronBio's portfolio extends beyond the ProStyle M® system, including artificial bioprosthetic heart valves, annuloplasty rings, and various cardiac surgical patches. The company's commitment to research and development continues to fuel advancements in the treatment of structural heart diseases, aiming to provide healthcare professionals with reliable solutions for patients suffering from moderate to severe mitral regurgitation.

Conclusion: A New Era for Cardiac Care

As the ProStyle M® system enters its confirmatory clinical study phase, promising results from prior research highlight its potential to revolutionize interventions for mitral regurgitation. KingstronBio's dedication to technological advancements reflects a bright future for cardiac healthcare, paving the way for safer, more effective treatments. With ongoing clinical trials, the hope remains that such innovations will lead to significant improvements in patient outcomes and healthcare standards. By addressing critical clinical challenges, KingstronBio is poised to make a lasting impact in the field of cardiology, championing a future where heart valve diseases can be managed more effectively.